Insulin aspart


Generic Medicine Info
Administration
Should be taken with food. Administer immediately before a meal.
Contraindications
Hypersensitivity. Episodes of hypoglycaemia.
Special Precautions
Patient with concomitant illness (e.g. infections or feverish conditions), adrenal, pituitary, or thyroid gland diseases. Renal and hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may impair the ability to concentrate and react due to hypoglycaemia, if affected, do not drive or operate machinery. Monitoring Parameters Monitor serum glucose, HBA1c, serum electrolytes, renal and hepatic function, and weight at regular intervals during therapy. Assess for signs of hypoglycaemia and hypokalaemia.
Adverse Reactions
Significant: Hypoglycaemia. Cardiac disorders: Chest pain. Gastrointestinal disorders: Nausea, vomiting, abdominal pain, diarrhoea. General disorders and administration site conditions: Lipodystrophy, inj site reactions, fever. Immune system disorders: Insulin antibody formation. Musculoskeletal and connective tissue disorders: Back pain. Nervous system disorders: Headache, hyporeflexia, sensory disturbance. Renal and urinary disorders: UTI. Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, rhinitis, sinusitis, viral respiratory tract infection. Skin and subcutaneous tissue disorders: Rash, eczema, pruritus, urticaria, dermatitis, onychomycosis.
Potentially Fatal: Severe hypoglycaemia and hypokalaemia. Hypersensitivity reactions (e.g. anaphylaxis).
Drug Interactions
Increased risk of fluid retention and heart failure with thiazolidinediones (e.g. pioglitazone). Increased risk of hypoglycaemia with oral antidiabetics, MAOIs, ACE inhibitors, salicylates, anabolic steroids, sulfonamide antibiotics, and GLP-1 receptor agonists. Decreased hypoglycaemic effect with oral contraceptives, thiazide diuretics, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone and danazol. β-blockers may mask the symptoms of hypoglycaemia. Increased or decreased hypoglycaemic effect with octreotide or lanreotide.
ATC Classification
A10AB05 - insulin aspart ; Belongs to the class of fast-acting insulins and analogues. Used in the treatment of diabetes.
A10AD05 - insulin aspart ; Belongs to the class of intermediate-acting combined with fast-acting insulins and analogues. Used in the treatment of diabetes.
Disclaimer: This information is independently developed by CIMS based on insulin aspart from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in